ATB Cormack and National Bank Raise Apotex Corp. Price Targets
ATB Cormack and National Bank raised their Apotex Corp. price targets to C$46.00 and C$45.50 and kept Outperform ratings, per Dow Jones Newswires.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
ATB Cormack raised its price target on Apotex Corp. to C$46.00 from C$40.00 and maintained an Outperform rating. National Bank also kept its Outperform rating and lifted its target to C$45.50 from C$43.00.
The ratings actions were reported by Dow Jones Newswires, citing Baystreet.
why it matters
Target revisions reflect analysts' updated estimates for the company. For a single stock, such changes are routine and matter mostly to investors who follow the company closely rather than to the broader market.
tags
instruments
sources
- Apotex Corp. Is Maintained at Outperform by ATB Cormack — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
- Apotex Corp. Is Maintained at Outperform by National Bank — Dow Jones Newswires, 13 November 2026 at 15:30 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗